ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin).
Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 69 citations in OpenAlex.
- Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer.British journal of cancer · 2012Trial
- Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid Correlates.JCO precision oncology · 2023Article
- Elimination of Osteosarcoma by Necroptosis with Graphene Oxide-Associated Anti-HER2 Antibodies.International journal of molecular sciences · 2019Review
- Gold Nanoparticles for Targeting Varlitinib to Human Pancreatic Cancer Cells.Pharmaceutics · 2018Article
- Article
- HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists.World journal of gastroenterology · 2016Review
- Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer.Oncotarget · 2015Article
- Clinical and molecular characterization of HER2 amplified-pancreatic cancer.Genome medicine · 2013Article
- KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer.Cancer research · 2012Article
- EGFR and HER2 expression in advanced biliary tract cancer.World journal of gastroenterology · 2009Article
- A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer.BMC surgery · 2009Article
- Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma.Journal of neuro-oncology · 2007Article
- Increasing of HER2 membranar density in human glioblastoma U251MG cell line established in a new nude mice model.Journal of neuro-oncology · 2006Article
- Recombinant humanised anti-HER2/neu antibody (Herceptin) induces cellular death of glioblastomas.British journal of cancer · 2004Article
- Incidence, mechanism and prognostic value of activated AKT in pancreas cancer.British journal of cancer · 2003Article
- New targeted therapies in gastrointestinal cancers.Current treatment options in oncology · 2003Review
- Tissue distribution and differential expression of melanocortin 1 receptor, a malignant melanoma marker.British journal of cancer · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The HER2/neu oncogene is overexpressed in human pancreatic cancer, but the clinical significance of that overexpression is uncertain. In the present study we investigated the antitumor efficacy of Herceptin, a new recombinant humanized anti-HER2/neu antibody, which exhibits cytostatic activity on breast and prostate cancer cells that overexpress the HER2 oncogene. That antibody may retard tumor growth in certain patients with those diseases. We quantified HER2 expression in various human pancreatic cancer cell lines and studied the bioactivity of this antibody both in vitro and in vivo. Growth inhibition by Herceptin was observed in vitro in cell lines with high levels of HER2/neu expression. Cell lines with low levels of this protein did not respond significantly to the antibody. In vivo we studied two different pancreatic cancer cell lines in an orthotopic mouse model of the disease. Herceptin treatment suppressed tumor growth in the MIA PaCa-2 tumor cell line, which expressed high levels of HER2/neu. These data suggest that Herceptin treatment of patients with pancreatic cancer who express high levels of the HER2/neu oncogene may be reasonable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.